Uncategorized
Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Company’s common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 a.m. to 4 p.m. ET to discuss teprotumumab, an investigational medicine for the treatment of Thyroid Eye Disease (TED). Teprotumumab is an investigational me